Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Feature|Articles|April 1, 2026
Top 10 urology headlines you missed in Q1 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look through the top 10 stories in urology from the past quarter.
Advertisement
Advertisement
The first quarter of 2026 brought a wave of pivotal developments across urology, from landmark clinical trial results to meaningful FDA actions reshaping treatment standards. Bladder and prostate cancer saw some of the most significant advances, with the KEYNOTE-B15 trial establishing a new perioperative standard of care in muscle-invasive disease and the PRIMARY2 trial offering a smarter diagnostic path that could spare men from unnecessary biopsies.
Related to this article
Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Advertisement
Advertisement